Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 13 studies | 25% ± 8% | |
epithelial cell | 9 studies | 39% ± 15% | |
adipocyte | 6 studies | 23% ± 5% | |
squamous epithelial cell | 4 studies | 39% ± 9% | |
enterocyte | 4 studies | 28% ± 11% | |
basal cell | 4 studies | 26% ± 9% | |
luminal cell of prostate epithelium | 4 studies | 31% ± 10% | |
glomerular endothelial cell | 3 studies | 38% ± 6% | |
secretory cell | 3 studies | 48% ± 13% | |
endothelial cell of lymphatic vessel | 3 studies | 17% ± 0% | |
brush cell | 3 studies | 27% ± 11% | |
mucus secreting cell | 3 studies | 25% ± 7% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
prostate | 3 studies | 29% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 2651.51 | 226 / 226 | 91% | 31.44 | 370 / 406 |
prostate | 96% | 3488.10 | 235 / 245 | 76% | 18.77 | 381 / 502 |
lung | 88% | 917.29 | 508 / 578 | 77% | 24.10 | 892 / 1155 |
breast | 91% | 1310.03 | 418 / 459 | 73% | 19.95 | 815 / 1118 |
stomach | 60% | 538.92 | 216 / 359 | 96% | 84.36 | 274 / 286 |
intestine | 58% | 7574.27 | 562 / 966 | 98% | 100.83 | 515 / 527 |
kidney | 100% | 4403.89 | 89 / 89 | 46% | 7.49 | 413 / 901 |
uterus | 74% | 730.86 | 125 / 170 | 64% | 21.39 | 295 / 459 |
bladder | 52% | 473.33 | 11 / 21 | 77% | 43.01 | 387 / 504 |
adrenal gland | 99% | 1669.90 | 256 / 258 | 28% | 4.92 | 65 / 230 |
esophagus | 44% | 3076.40 | 635 / 1445 | 75% | 46.09 | 138 / 183 |
skin | 40% | 310.56 | 727 / 1809 | 78% | 52.41 | 370 / 472 |
spleen | 99% | 1318.29 | 238 / 241 | 0% | 0 | 0 / 0 |
pancreas | 6% | 31.61 | 21 / 328 | 92% | 42.33 | 164 / 178 |
peripheral blood | 90% | 3812.34 | 833 / 929 | 0% | 0 | 0 / 0 |
thymus | 79% | 534.68 | 516 / 653 | 6% | 0.76 | 36 / 605 |
tonsil | 0% | 0 | 0 / 0 | 73% | 21.62 | 33 / 45 |
adipose | 59% | 969.03 | 714 / 1204 | 0% | 0 | 0 / 0 |
ovary | 16% | 74.74 | 29 / 180 | 27% | 4.06 | 115 / 430 |
eye | 0% | 0 | 0 / 0 | 35% | 4.73 | 28 / 80 |
lymph node | 0% | 0 | 0 / 0 | 31% | 4.71 | 9 / 29 |
heart | 28% | 148.39 | 237 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 2% | 11.69 | 27 / 1335 | 0% | 0 | 0 / 0 |
muscle | 2% | 7.27 | 13 / 803 | 0% | 0 | 0 / 0 |
brain | 0% | 3.32 | 8 / 2642 | 0% | 0.05 | 2 / 705 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051896 | Biological process | regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0051055 | Biological process | negative regulation of lipid biosynthetic process |
GO_0001525 | Biological process | angiogenesis |
GO_0098742 | Biological process | cell-cell adhesion via plasma-membrane adhesion molecules |
GO_0060312 | Biological process | regulation of blood vessel remodeling |
GO_0006469 | Biological process | negative regulation of protein kinase activity |
GO_0032869 | Biological process | cellular response to insulin stimulus |
GO_0001558 | Biological process | regulation of cell growth |
GO_0032692 | Biological process | negative regulation of interleukin-1 production |
GO_0070372 | Biological process | regulation of ERK1 and ERK2 cascade |
GO_0050860 | Biological process | negative regulation of T cell receptor signaling pathway |
GO_0043116 | Biological process | negative regulation of vascular permeability |
GO_0007165 | Biological process | signal transduction |
GO_0010594 | Biological process | regulation of endothelial cell migration |
GO_1903670 | Biological process | regulation of sprouting angiogenesis |
GO_0001915 | Biological process | negative regulation of T cell mediated cytotoxicity |
GO_0007155 | Biological process | cell adhesion |
GO_0002682 | Biological process | regulation of immune system process |
GO_0043318 | Biological process | negative regulation of cytotoxic T cell degranulation |
GO_0090331 | Biological process | negative regulation of platelet aggregation |
GO_0042058 | Biological process | regulation of epidermal growth factor receptor signaling pathway |
GO_0015721 | Biological process | bile acid and bile salt transport |
GO_1903385 | Biological process | regulation of homophilic cell adhesion |
GO_0007229 | Biological process | integrin-mediated signaling pathway |
GO_0002859 | Biological process | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target |
GO_0045601 | Biological process | regulation of endothelial cell differentiation |
GO_0038158 | Biological process | granulocyte colony-stimulating factor signaling pathway |
GO_0007156 | Biological process | homophilic cell adhesion via plasma membrane adhesion molecules |
GO_0030334 | Biological process | regulation of cell migration |
GO_0030853 | Biological process | negative regulation of granulocyte differentiation |
GO_2000346 | Biological process | negative regulation of hepatocyte proliferation |
GO_0044319 | Biological process | wound healing, spreading of cells |
GO_0045717 | Biological process | negative regulation of fatty acid biosynthetic process |
GO_0001568 | Biological process | blood vessel development |
GO_0035726 | Biological process | common myeloid progenitor cell proliferation |
GO_1901143 | Biological process | insulin catabolic process |
GO_2001214 | Biological process | positive regulation of vasculogenesis |
GO_0038016 | Biological process | insulin receptor internalization |
GO_0016477 | Biological process | cell migration |
GO_0016324 | Cellular component | apical plasma membrane |
GO_0035579 | Cellular component | specific granule membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0031528 | Cellular component | microvillus membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0009925 | Cellular component | basal plasma membrane |
GO_0005911 | Cellular component | cell-cell junction |
GO_0009986 | Cellular component | cell surface |
GO_0005912 | Cellular component | adherens junction |
GO_0070821 | Cellular component | tertiary granule membrane |
GO_0016328 | Cellular component | lateral plasma membrane |
GO_0030054 | Cellular component | cell junction |
GO_0042101 | Cellular component | T cell receptor complex |
GO_0030658 | Cellular component | transport vesicle membrane |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0015125 | Molecular function | bile acid transmembrane transporter activity |
GO_0031005 | Molecular function | filamin binding |
GO_0019903 | Molecular function | protein phosphatase binding |
GO_0019900 | Molecular function | kinase binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0003779 | Molecular function | actin binding |
GO_1990782 | Molecular function | protein tyrosine kinase binding |
GO_0005516 | Molecular function | calmodulin binding |
GO_0046983 | Molecular function | protein dimerization activity |
GO_0005515 | Molecular function | protein binding |
GO_0003674 | Molecular function | molecular_function |
Gene name | CEACAM1 |
Protein name | CEACAM1 protein Carcinoembryonic antigen-related cell adhesion molecule 1 (Biliary glycoprotein 1) (BGP-1) (CD antigen CD66a) CEA cell adhesion molecule 1 |
Synonyms | BGP BGP1 |
Description | FUNCTION: [Isoform 1]: Cell adhesion protein that mediates homophilic cell adhesion in a calcium-independent manner (By similarity). Plays a role as coinhibitory receptor in immune response, insulin action and functions also as an activator during angiogenesis . Its coinhibitory receptor function is phosphorylation- and PTPN6 -dependent, which in turn, suppress signal transduction of associated receptors by dephosphorylation of their downstream effectors. Plays a role in immune response, of T cells, natural killer (NK) and neutrophils . Upon TCR/CD3 complex stimulation, inhibits TCR-mediated cytotoxicity by blocking granule exocytosis by mediating homophilic binding to adjacent cells, allowing interaction with and phosphorylation by LCK and interaction with the TCR/CD3 complex which recruits PTPN6 resulting in dephosphorylation of CD247 and ZAP70 . Also inhibits T cell proliferation and cytokine production through inhibition of JNK cascade and plays a crucial role in regulating autoimmunity and anti-tumor immunity by inhibiting T cell through its interaction with HAVCR2 . Upon natural killer (NK) cells activation, inhibit KLRK1-mediated cytolysis of CEACAM1-bearing tumor cells by trans-homophilic interactions with CEACAM1 on the target cell and lead to cis-interaction between CEACAM1 and KLRK1, allowing PTPN6 recruitment and then VAV1 dephosphorylation . Upon neutrophils activation negatively regulates IL1B production by recruiting PTPN6 to a SYK-TLR4-CEACAM1 complex, that dephosphorylates SYK, reducing the production of reactive oxygen species (ROS) and lysosome disruption, which in turn, reduces the activity of the inflammasome. Down-regulates neutrophil production by acting as a coinhibitory receptor for CSF3R by down-regulating the CSF3R-STAT3 pathway through recruitment of PTPN6 that dephosphorylates CSF3R (By similarity). Also regulates insulin action by promoting INS clearance and regulating lipogenesis in liver through regulating insulin signaling (By similarity). Upon INS stimulation, undergoes phosphorylation by INSR leading to INS clearance by increasing receptor-mediated insulin endocytosis. This inernalization promotes interaction with FASN leading to receptor-mediated insulin degradation and to reduction of FASN activity leading to negative regulation of fatty acid synthesis. INSR-mediated phosphorylation also provokes a down-regulation of cell proliferation through SHC1 interaction resulting in decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 and phosphatidylinositol 3-kinase pathways (By similarity). Functions as activator in angiogenesis by promoting blood vessel remodeling through endothelial cell differentiation and migration and in arteriogenesis by increasing the number of collateral arteries and collateral vessel calibers after ischemia. Also regulates vascular permeability through the VEGFR2 signaling pathway resulting in control of nitric oxide production (By similarity). Down-regulates cell growth in response to EGF through its interaction with SHC1 that mediates interaction with EGFR resulting in decrease coupling of SHC1 to the MAPK3/ERK1-MAPK1/ERK2 pathway (By similarity). Negatively regulates platelet aggregation by decreasing platelet adhesion on type I collagen through the GPVI-FcRgamma complex (By similarity). Inhibits cell migration and cell scattering through interaction with FLNA; interferes with the interaction of FLNA with RALA . Mediates bile acid transport activity in a phosphorylation dependent manner (By similarity). Negatively regulates osteoclastogenesis (By similarity). .; FUNCTION: [Isoform 8]: Cell adhesion protein that mediates homophilic cell adhesion in a calcium-independent manner (By similarity). Promotes populations of T cells regulating IgA production and secretion associated with control of the commensal microbiota and resistance to enteropathogens (By similarity). . |
Accessions | M0R2K4 A0A7I2V3A7 ENST00000471298.2 ENST00000676851.1 ENST00000161559.11 [P13688-1] ENST00000403444.7 [P13688-8] ENST00000358394.7 [P13688-5] ENST00000403461.5 [P13688-11] M0R109 ENST00000352591.9 [P13688-6] ENST00000599389.1 [P13688-9] P13688 Q3KRG8 ENST00000600172.1 |